Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
autoimmune skin toxicity
biomarker
immune checkpoint inhibitor
immune-related adverse event
pneumonitis
self-antigen
Journal
Immunological reviews
ISSN: 1600-065X
Titre abrégé: Immunol Rev
Pays: England
ID NLM: 7702118
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
28
02
2023
accepted:
29
06
2023
medline:
25
9
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. However, their use is frequently associated with immune-related adverse events (irAEs) potentially affecting any organ. The mechanisms mediating such irAEs remain poorly understood and biomarkers to predict the development of irAEs are lacking. Growing evidence shows the importance of self-antigens in mediating irAEs during ICI therapy, in particular the well-described melanocyte differentiation antigens in melanoma patients. This review will focus on two novel classes of self-antigens involved in mediating autoimmune skin toxicity and pneumonitis in non-small cell lung cancer patients treated with immunotherapy. T cells specific for these self-antigens are thought to not only mediate irAEs but are thought to simultaneously mediate anti-tumor responses and are therefore associated with both autoimmune toxicity and response to ICI therapy. We further discuss emerging cellular and proteomic immune signatures of irAEs that may serve as biomarkers to help predict which patients are at higher risk of developing these irAEs. The determination of new tumor antigens involved in ICI therapy and the identification of related biomarkers brings us a step forward in the mechanistic understanding of ICIs and will help to monitor patients at higher risk of developing irAEs. Lastly, we discuss the current challenges in collecting research samples for the study of ICI-related mechanisms and in distinguishing between immune signatures of response and those of irAEs.
Substances chimiques
Immune Checkpoint Inhibitors
0
Autoantigens
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-50Informations de copyright
© 2023 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
Références
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330. doi:10.1056/NEJMoa1412082
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639. doi:10.1056/NEJMoa1507643
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet. 2017;389(10066):255-265. doi:10.1016/s0140-6736(16)32517-x
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813. doi:10.1056/NEJMoa1510665
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-1026. doi:10.1056/NEJMoa1613683
Petrelli F, Grizzi G, Ghidini M, et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother. 2020;43(1):1-7. doi:10.1097/CJI.0000000000000300
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481
Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol. 2020;64:93-101. doi:10.1016/j.semcancer.2019.06.012
Ellithi M, Elnair R, Chang GV, Abdallah MA. Toxicities of immune checkpoint inhibitors: itis-ending adverse reactions and more. Cureus. 2020;12(2):e6935. doi:10.7759/cureus.6935
Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. doi:10.1038/s41572-020-0160-6
Esfahani K, Elkrief A, Calabrese C, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504-515. doi:10.1038/s41571-020-0352-8
Berner F, Bomze D, Diem S, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncologia. 2019;5(7):1043-1047. doi:10.1001/jamaoncol.2019.0402
Berner F, Niederer R, Luimstra JJ, et al. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. Onco Targets Ther. 2021;10(1):2006893. doi:10.1080/2162402X.2021.2006893
Berner F, Bomze D, Lichtensteiger C, et al. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Science Immunology. 2022;7(75). doi:10.1126/sciimmunol.abn9644
Nuñez NG, Berner F, Friebel E, et al. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y). 2023:113-129. doi:10.1016/j.medj.2022.12.007
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133-150. doi:10.1038/s41568-019-0116-x
Bomze D, Hasan Ali O, Bate A, Flatz L. Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. JAMA Oncol. 2019;5(11):1633-1635. doi:10.1001/jamaoncol.2019.3221
Fan Y, Xie W, Huang H, et al. Association of Immune Related Adverse Events with Efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Front Oncol. 2021;11:633032. doi:10.3389/fonc.2021.633032
Hussaini S, Chehade R, Boldt RG, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134. doi:10.1016/j.ctrv.2020.102134
Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):87. doi:10.1186/s12916-020-01549-2
Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886-894. doi:10.1158/1078-0432.CCR-15-1136
Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA. Oncologia. 2018;4(12):1721-1728. doi:10.1001/jamaoncol.2018.3923
Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-Related Adverse Events with Nivolumab Efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4(3):374-378. doi:10.1001/jamaoncol.2017.2925
Liu CC, Yang H, Zhang R, Zhao JJ, Hao DJ. Tumour-associated antigens and their anti-cancer applications. Eur J Cancer Care (Engl). 2017;26(5). doi:10.1111/ecc.12446
Engelhard VH, Bullock TNJ, Colella TA, Sheasley SL, Mullins DW. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev. 2002;188:136-146. doi:10.1034/j.1600-065x.2002.18812.x
Nardin C, Jeand'heur A, Bouiller K, et al. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients. J Am Acad Dermatol. 2020;82(3):770-772. doi:10.1016/j.jaad.2019.11.017
Palermo B, Campanelli R, Garbelli S, et al. Specific cytotoxic T lymphocyte responses against Melan-a/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol. 2001;117(2):326-332. doi:10.1046/j.1523-1747.2001.01408.x
Pitcovski J, Shahar E, Aizenshtein E, Gorodetsky R. Melanoma antigens and related immunological markers. Crit Rev Oncol Hematol. 2017;115:36-49. doi:10.1016/j.critrevonc.2017.05.001
Park J, Talukder AH, Lim SA, et al. SLC45A2: a melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity. Cancer Immunol Res. 2017;5(8):618-629. doi:10.1158/2326-6066.CIR-17-0051
Naughton GK, Eisinger M, Bystryn JC. Antibodies to normal human melanocytes in vitiligo. J Exp Med. 1983;158(1):246-251. doi:10.1084/jem.158.1.246
Bystryn JC, Naughton GK. The significance of vitiligo antibodies. J Dermatol. 1985;12(1):1-9. doi:10.1111/j.1346-8138.1985.tb01532.x
Fassler M, Diem S, Mangana J, et al. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer. 2019;7(1):50. doi:10.1186/s40425-019-0523-2
Hasan Ali O, Bomze D, Ring SS, et al. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol. 2020;82(4):854-861. doi:10.1016/j.jaad.2019.08.045
Cancer Genome Atlas Research N. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681-1696. doi:10.1016/j.cell.2015.05.044
Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas Pan-cancer analysis project. Nat Genet. 2013;45(10):1113-1120. doi:10.1038/ng.2764
Reemann P, Reimann E, Ilmjarv S, et al. Melanocytes in the skin-comparative whole transcriptome analysis of main skin cell types. PloS One. 2014;9(12):e115717. doi:10.1371/journal.pone.0115717
Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14(7). doi:10.1186/1471-2105-14-7
Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3(9):666-675. doi:10.1038/nrc1167
Vaddepally R, Doddamani R, Sodavarapu S, et al. Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)-their incidence, management, multiorgan irAEs, and Rechallenge. Biomedicines. 2022;10(4). doi:10.3390/biomedicines10040790
Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv119-iv142. doi:10.1093/annonc/mdx225
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-1768. doi:10.1200/JCO.2017.77.6385
Hasan Ali O, Diem S, Markert E, et al. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Onco Targets Ther. 2016;5(11):e1231292. doi:10.1080/2162402X.2016.1231292
Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-525. doi:10.1038/nature11404
Consortium TEP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74. doi:10.1038/nature11247
Consortium GT. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45(6):580-585. doi:10.1038/ng.2653
Thoma-Uszynski S, Uter W, Schwietzke S, et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol. 2004;122(6):1413-1422. doi:10.1111/j.0022-202X.2004.22603.x
Vorobyev A, Ludwig RJ, Schmidt E. Clinical features and diagnosis of epidermolysis bullosa acquisita. Expert Rev Clin Immunol. 2017;13(2):157-169. doi:10.1080/1744666x.2016.1221343
Kim Y, Ponomarenko J, Zhu Z, et al. Immune epitope database analysis resource. Nucleic Acids Res. 2012;40(Web Server issue):W525-W530. doi:10.1093/nar/gks438
Fleri W, Paul S, Dhanda SK, et al. The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. Front Immunol. 2017;8:278. doi:10.3389/fimmu.2017.00278
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA. Oncologia. 2016;2(12):1607-1616. doi:10.1001/jamaoncol.2016.2453
Ma K, Lu Y, Jiang S, Tang J, Li X, Zhang Y. The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis. Front Pharmacol. 2018;9:1430. doi:10.3389/fphar.2018.01430
Suresh K, Psoter KJ, Voong KR, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol. 2019;14(3):494-502. doi:10.1016/j.jtho.2018.11.016
Han S, Mallampalli RK. The role of surfactant in lung disease and host defense against pulmonary infections. Ann Am Thorac Soc. 2015;12(5):765-774. doi:10.1513/AnnalsATS.201411-507FR
Weidemann S, Bohle JL, Contreras H, et al. Napsin a expression in human tumors and Normal tissues. Pathol Oncol Res. 2021;27:613099. doi:10.3389/pore.2021.613099
Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin a, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136(2):163-171. doi:10.5858/arpa.2011-0320-OA
Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-1755. doi:10.1056/NEJMoa1609214
Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579-1589. doi:10.1016/s1470-2045(18)30608-9
Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest. 2021;131(5). doi:10.1172/jci145186
Zamami Y, Niimura T, Okada N, et al. Factors associated with immune checkpoint inhibitor-related myocarditis. JAMA Oncologia. 2019;5(11):1635-1637. doi:10.1001/jamaoncol.2019.3113
Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636-2648. doi:10.1093/eurheartj/eht210
Zhang L, Zlotoff DA, Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020;141(24):2031-2034. doi:10.1161/circulationaha.119.044703
Axelrod ML, Meijers WC, Screever EM, et al. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818-826. doi:10.1038/s41586-022-05432-3
Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol. 2006;177(11):8234-8240. doi:10.4049/jimmunol.177.11.8234
Stavrakis S, Yu X, Patterson E, et al. Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. J Am Coll Cardiol. 2009;54(14):1309-1316. doi:10.1016/j.jacc.2009.07.015
Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of checkpoint inhibitor induced immune-related adverse events-a comprehensive review. Front Oncol. 2020;10:585311. doi:10.3389/fonc.2020.585311
Wölffer M, Battke F, Schulze M, et al. Biomarkers associated with immune-related adverse events under checkpoint inhibitors in metastatic melanoma. Cancers (Basel). 2022;14(2). doi:10.3390/cancers14020302
Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and Rechallenging immune checkpoint inhibitors. Front Immunol. 2022;13:779691. doi:10.3389/fimmu.2022.779691
Koh J, Hur JY, Lee KY, et al. Regulatory (FoxP3[+]) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep. 2020;10(1):18994. doi:10.1038/s41598-020-76130-1
Lozano AX, Chaudhuri AA, Nene A, et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022;28(2):353-362. doi:10.1038/s41591-021-01623-z
Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res. 2019;25(5):1557-1563. doi:10.1158/1078-0432.CCR-18-2795
Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454-461. doi:10.1038/s41591-019-0357-y
Kim KH, Cho J, Ku BM, et al. The first-week proliferative response of peripheral blood PD-1(+)CD8(+) T cells predicts the response to anti-PD-1 therapy in solid tumors. Clin Cancer Res. 2019;25(7):2144-2154. doi:10.1158/1078-0432.CCR-18-1449
Paternoster L, Standl M, Waage J, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449-1456. doi:10.1038/ng.3424
Park H, Ahn K, Park MH, Lee SI. The HLA-DRB1 polymorphism is associated with atopic dermatitis, but not egg allergy in Korean children. Allergy Asthma Immunol Res. 2012;4(3):143-149. doi:10.4168/aair.2012.4.3.143
Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015;47(2):172-179. doi:10.1038/ng.3176
Jacobson EM, Huber A, Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun. 2008;30(1-2):58-62. doi:10.1016/j.jaut.2007.11.010
Chu X, Pan CM, Zhao SX, et al. A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet. 2011;43(9):897-901. doi:10.1038/ng.898
Lenz TL, Deutsch AJ, Han B, et al. Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. Nat Genet. 2015;47(9):1085-1090. doi:10.1038/ng.3379
Hayashi M, Jin Y, Yorgov D, et al. Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. Proc Natl Acad Sci U S A. 2016;113(5):1357-1362. doi:10.1073/pnas.1525001113
Heaney AP, Sumerel B, Rajalingam R, Bergsneider M, Yong WH, Liau LM. HLA markers DQ8 and DR53 are associated with lymphocytic Hypophysitis and may aid in differential diagnosis. J Clin Endocrinol Metab. 2015;100(11):4092-4097. doi:10.1210/jc.2015-2702
Yano S, Ashida K, Sakamoto R, et al. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur J Cancer. 2020;130:198-203. doi:10.1016/j.ejca.2020.02.049
Inaba H, Kaido Y, Ito S, et al. Human leukocyte antigens and biomarkers in type 1 diabetes mellitus induced by immune-checkpoint inhibitors. Endocrinol Metab (Seoul). 2022;37(1):84-95. doi:10.3803/EnM.2021.1282
Correale P, Saladino RE, Giannarelli D, et al. HLA expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis. Cell. 2020;9(9). doi:10.3390/cells9091964
Akturk HK, Couts KL, Baschal EE, et al. Analysis of human leukocyte antigen DR alleles, immune-related adverse events, and survival associated with immune checkpoint inhibitor use among patients with advanced malignant melanoma. JAMA Netw Open. 2022;5(12):e2246400. doi:10.1001/jamanetworkopen.2022.46400
Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471-1480. doi:10.2337/dbi18-0002
Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). 2019;58(3):476-480. doi:10.1093/rheumatology/key358
Hasan Ali O, Berner F, Bomze D, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2019;107:8-14. doi:10.1016/j.ejca.2018.11.009